Vectibix er indiceret som monoterapi til patienter med EGFR- eksprimerende, metastatisk colorectalt carcinom, hvis tumorer indeholder ikke- muteret (vildtypen) KRAS, når kemoterapi- regimener, der indeholder fluoropyrimidin, oxaliplatin og irinotecan, har fejlet.
Vectibix is indicated as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.